Clinical study of tirofiban combined with oxiracetam in the treatment of acute progressive cerebral infarction

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400087048

Enrollment

Unknown

Registered

2024-07-18

Start date

2024-07-20

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic cerebrovascular disease

Interventions

Control group:conventional therapy

combination group:Conventional treatment combined with tirofiban and oxiracetam

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Those who meet the diagnostic criteria for acute progressive cerebral infarction. 2. The age range is between 40 and 80 years old, regardless of gender. 3. The process of obtaining informed consent from patients complies with GCP regulations.

Exclusion criteria

Exclusion criteria: 1. Hemorrhagic cerebrovascular disease caused by hypertension and other factors. 2. Other traditional Chinese and Western medicines for the treatment of acute progressive cerebral infarction have been used since the onset of this disease. 3. Pregnant and lactating women. 4. Severe primary heart, liver, lung, kidney, blood or serious diseases that affect their survival, such as cardiogenic shock, liver cancer, lung cancer, uremia, aplastic anemia, and leukemia. 5. Individuals who are unable to provide sufficient informed consent due to intellectual or behavioral impairments. 6. Suspect or have a history of alcohol or drug abuse. 7. According to the researcher's judgment, other lesions that may reduce the likelihood of enrollment or complicate enrollment, such as frequent changes in the work environment, may lead to loss of follow-up. 8. Allergic constitution, such as those with a history of allergies to two or more drugs or foods; Or known to be allergic to the ingredients of this medicine. 9. Patients who are participating in clinical trials of other drugs.

Design outcomes

Primary

Measure	Time frame
NIHSS score;MMSE;montreal cognitive assessment;	—

Secondary

Measure	Time frame
Relative diffusion coefficient of ischemic penumbra;Area of ischemia hypoperfusion zone and ischemic center zone;Proportion of ischemic penumbra after treatment;C3 and C4 levels;CD4+, CD8+, and CD4+/CD8+levels;	—

Countries

China

Contacts

Public ContactYong Liu

Hebei Cangzhou Integrated Traditional Chinese and Western Medicine Hospital

812189239@qq.com+86 181 3177 6806

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026